
Neogen Corporation NEOG
$ 9.93
3.82%
Quarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Depreciation & Amortization 2011-2026 | NEOG
Annual Depreciation & Amortization Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119 M | 117 M | 88.4 M | 23.7 M | 21 M | 18.4 M | 17.6 M | 17.1 M | 14.7 M | 12.2 M | 10.6 M | 9.18 M | 7.41 M | 6.17 M | 5.33 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | 5.33 M | 32.5 M |
Quarterly Depreciation & Amortization Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 29.1 M | - | - | - | 29.8 M | - | 23.7 M | 23.7 M | 28.7 M | - | 22.9 M | 22.7 M | 5.73 M | 32.5 M | 2.6 M | 2.4 M | 5.68 M | 11.5 M | - | - | 4.72 M | 9.52 M | - | - | 4.44 M | 8.98 M | 4.44 M | - | 4.27 M | 8.6 M | 4.27 M | - | 3.99 M | 8.27 M | 3.99 M | - | 3.48 M | 7.04 M | 3.48 M | - | 2.7 M | 5.68 M | - | - | 2.52 M | 5.17 M | 2.52 M | - | 2.03 M | 4.17 M | 2.03 M | - | 1.63 M | 3.29 M | 1.63 M | - | 1.38 M | 2.91 M | 1.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 32.5 M | 1.38 M | 8.77 M |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
321 M | $ 113.25 | -1.38 % | $ 34.4 B | ||
|
CareDx, Inc
CDNA
|
15 M | $ 17.42 | -2.24 % | $ 928 M | ||
|
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
47.8 M | $ 16.35 | 0.28 % | $ 172 M | ||
|
Co-Diagnostics
CODX
|
1.11 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Danaher Corporation
DHR
|
750 M | $ 189.05 | -1.58 % | $ 135 B | ||
|
Aspira Women's Health
AWH
|
112 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
252 M | $ 63.32 | 0.17 % | $ 24.7 B | ||
|
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | ||
|
Charles River Laboratories International
CRL
|
403 M | $ 166.89 | -0.79 % | $ 8.27 B | ||
|
Castle Biosciences
CSTL
|
16 M | $ 24.75 | 0.08 % | $ 687 M | ||
|
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
5.77 M | $ 14.37 | -6.48 % | $ 1.86 B | ||
|
Fulgent Genetics
FLGT
|
24.9 M | $ 15.98 | -2.68 % | $ 483 M | ||
|
Guardant Health
GH
|
39.7 M | $ 90.17 | 0.56 % | $ 11.3 B | ||
|
QIAGEN N.V.
QGEN
|
194 M | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
38.3 K | $ 2.61 | 0.58 % | $ 84.7 K | ||
|
ICON Public Limited Company
ICLR
|
488 M | $ 107.87 | -1.6 % | $ 8.9 B | ||
|
Illumina
ILMN
|
354 M | $ 126.04 | -1.33 % | $ 20 B | ||
|
Biomerica
BMRA
|
87 K | $ 2.13 | -1.84 % | $ 4.89 M | ||
|
BioNano Genomics
BNGO
|
9.53 M | $ 1.15 | -0.43 % | $ 6.26 M | ||
|
Interpace Biosciences
IDXG
|
425 K | $ 1.98 | 0.51 % | $ 8.76 M | ||
|
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M | ||
|
Laboratory Corporation of America Holdings
LH
|
681 M | $ 271.93 | -0.96 % | $ 22.6 B | ||
|
Lantheus Holdings
LNTH
|
70.1 M | $ 76.19 | 0.4 % | $ 5.14 B | ||
|
Celcuity
CELC
|
167 K | $ 113.92 | -0.26 % | $ 5.33 B | ||
|
Medpace Holdings
MEDP
|
27.2 M | $ 501.47 | 1.1 % | $ 14.5 B | ||
|
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | ||
|
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | ||
|
Myriad Genetics
MYGN
|
53.7 M | $ 4.64 | -0.54 % | $ 430 M | ||
|
NeoGenomics
NEO
|
36.1 M | $ 7.9 | -1.5 % | $ 1.01 B | ||
|
Exact Sciences Corporation
EXAS
|
125 M | - | - | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
570 M | $ 198.9 | -0.08 % | $ 22.1 B | ||
|
National Research Corporation
NRC
|
7.62 M | $ 17.07 | -1.5 % | $ 382 M | ||
|
Natera
NTRA
|
16.7 M | $ 206.47 | 0.78 % | $ 20.3 B | ||
|
ENDRA Life Sciences
NDRA
|
44 K | $ 4.71 | -0.74 % | $ 3.71 M | ||
|
Pacific Biosciences of California
PACB
|
13 M | $ 1.42 | - | $ 426 M | ||
|
Precipio
PRPO
|
1.24 M | $ 26.03 | 0.19 % | $ 41.8 M | ||
|
Personalis
PSNL
|
10.9 M | $ 6.03 | -8.36 % | $ 357 M | ||
|
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B |